Fractyl Health has received approval to begin a first-in-human study of a new gene therapy called RJVA-001, aimed at treating type 2 diabetes. This therapy is designed to help the pancreas produce a hormone called GLP-1, which plays a crucial role in regulating blood sugar levels. Unlike traditional GLP-1 treatments that require ongoing medication, RJVA-001 is a one-time treatment that uses a virus to deliver the gene directly to pancreatic cells through a minimally invasive procedure.

This development is significant for adults aged 35 to 70 who struggle with type 2 diabetes, especially those who have not achieved adequate blood sugar control despite using multiple medications. If successful, RJVA-001 could offer a more effective and convenient option for managing diabetes, potentially improving blood sugar levels and reducing the need for daily medication. The study will monitor participants for safety and effectiveness over 12 months, with long-term follow-up extending up to five years.

Currently, the research is in the early stages, with a Phase 1/2 trial set to enroll a small number of participants. While the initial results are expected in late 2026, it’s important to note that this therapy has not yet been proven effective in larger populations or approved by regulatory agencies like the U.S. Food and Drug Administration. Therefore, while the potential is promising, it’s too early to draw definitive conclusions about its effectiveness for broader use.

Source: longevity.technology